Latest Ratios: P/E Ratio -21.0x · EV/EBITDA N/A · ROE -6.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $200M | $86M | $79M | $197M | $296M | $872M | — | — |
| Enterprise Value | $182M | $68M | $75M | $198M | $261M | $841M | — | — |
| P/E Ratio → | -21.00 | — | — | — | — | — | — | — |
| P/S Ratio | 1.83 | 0.79 | 12.06 | 88.11 | 56.99 | — | — | — |
| P/B Ratio | 1.26 | 0.54 | 0.49 | 1.07 | 0.98 | 2.20 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 21.09 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.62 | 11.36 | 88.49 | 50.29 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.0% | 88.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -13.8% | -13.8% | -2096.5% | -6556.9% | -2574.2% | — | — | — |
| Net Profit Margin | -8.8% | -8.8% | -1920.9% | -6115.1% | -2518.4% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -6.0% | -6.0% | -73.1% | -56.1% | -37.5% | -66.1% | — | — |
| ROA | -3.3% | -3.3% | -35.5% | -32.3% | -28.3% | -35.2% | -54.2% | -269.3% |
| ROIC | -7.6% | -7.6% | -60.5% | -48.5% | -31.7% | -56.3% | — | — |
| ROCE | -7.0% | -7.0% | -48.8% | -36.7% | -30.5% | -36.7% | -53.9% | -22.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | 0.33 | 0.26 | 0.16 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.12 | -0.03 | 0.00 | -0.12 | -0.08 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -248.61 | — | -74.12 | -139.62 | — |
Net cash position: cash ($62M) exceeds total debt ($44M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.97 | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 |
| Quick Ratio | 5.97 | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 |
| Cash Ratio | 5.79 | 5.79 | 1.46 | 9.68 | 10.58 | 14.24 | 6.25 | 27.23 |
| Asset Turnover | — | 0.49 | 0.02 | 0.01 | 0.01 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 2.23 | 84.20 | 108.60 | 54.76 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $87M | $79M | $59M | $58M | $55M | $55M | $55M |
Clinical milestone dependency risk
Based on reported figures, Century Therapeutics trades at a price-to-sales ratio of 1.84, which appears to be a speculative valuation given that revenue is entirely derived from non-recurring collaboration milestones rather than a sustainable, recurring commercial product stream typical of established healthcare industry participants.
The lack of a meaningful P/E or EV/EBITDA multiple underscores the company's pre-commercial status and reliance on future clinical success. Investors should monitor whether the current P/B of 1.26 represents a floor or if further erosion of the equity base will necessitate a downward re-rating of the firm's valuation.
According to recent SEC filings, the company's ROIC has fluctuated significantly, reaching a temporary peak of 28% in 2025Q1 before reverting to negative territory, which highlights the inherent volatility of a business model that lacks consistent, self-sustaining returns on its invested capital base.
The negative ROIC trend suggests that the company is currently destroying value through its heavy R&D spending relative to the capital deployed. This pattern warrants further investigation into whether the proprietary allo-evasion platform can eventually achieve the scale necessary to generate positive returns on invested capital.
As reported in financial statements, the company's current ratio has tightened from over 12.0 in early 2024 to approximately 10.25 in 2026Q1, indicating that while the firm maintains a high liquidity position, it is rapidly consuming cash to fund its ongoing clinical development and research initiatives.
The high current ratio is somewhat misleading as it is heavily influenced by the timing of milestone-related cash inflows rather than operational efficiency. Investors should monitor the cash burn rate closely, as the current liquidity position may be insufficient to support the company's multi-candidate clinical ambitions without further financing.
Based on the provided data, the gross margin ratio is the most commonly misapplied metric for this business model, as it creates a false impression of profitability by failing to account for the massive, non-recurring nature of collaboration revenue recognition versus ongoing R&D costs.
Relying on gross margin to assess the company's earning power is fundamentally flawed because it ignores the underlying cash-burning nature of the business. Analysts should instead focus on the net burn rate and the velocity of milestone achievement to better understand the company's true financial health.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IPSC stock.
Century Therapeutics, Inc.'s current P/E ratio is -21.0x. This places it at the 50th percentile of its historical range.
Century Therapeutics, Inc.'s return on equity (ROE) is -6.0%. The historical average is -47.8%.
Based on historical data, Century Therapeutics, Inc. is trading at a P/E of -21.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Century Therapeutics, Inc. has 88.0% gross margin and -13.8% operating margin.